Lilly lowers Zepbound single-dose vial prices for cash-paying patients to $299 to $449 a month

Zepbound (tirzepatide) vials bought with cash on LillyDirect got cheaper on December 1, 2025, when Eli Lilly announced self-pay prices of $299 to $449 a month depending on dose ^[1][2].

The 2.5 mg starting dose now sells for $299, down from $349. The 5 mg dose is $399, down from $499. The 7.5 mg, 10 mg, 12.5 mg and 15 mg vials each cost $449, down from $499 ^[1]. In dollar terms, the 2.5 mg vial fell $50, the 5 mg vial fell $100, and the four larger sizes fell $50 each ^[1][3].

Those $449 prices depend on refill timing. Lilly's Self Pay Journey Program applies that rate to a first fill and to refills delivered within 45 days of the previous one ^[1]. A prescription refilled later falls to the regular monthly prices listed in the release: $599 for 7.5 mg, $699 for 10 mg, $849 for 12.5 mg and $1,049 for 15 mg ^[1]. A LillyDirect product page for the same vials lists regular prices of $499 for 7.5 mg and $699 for 10 mg, 12.5 mg and 15 mg ^[4]. The two Lilly sources do not match, and the company has not explained the difference.

For scale, Zepbound's list price is roughly $1,086 per month ^[2]. The vials are the version a patient draws up with a syringe and needle; Lilly began offering that form in August 2024 ^[2]. Vials are cash-only on LillyDirect, which also connects patients with independent telehealth providers ^[3][4].

"Far too many people who need obesity treatments still face cost and coverage barriers," Ilya Yuffa, executive vice president and president of Lilly USA and Global Customer Capabilities, said in the release. "Today's action underscores Lilly's commitment to improving access across the obesity care landscape." ^[1][3]

The move follows price cuts at rival Novo Nordisk, which in November lowered cash prices for Wegovy and Ozempic, both semaglutide, to $349 a month from $499 for existing self-paying patients, excluding Ozempic's highest dose. New cash payers there can get the two lowest doses of either drug for $199 a month during their first two months of treatment ^[2][3].

Why it matters for patients

Obesity and sleep apnea treatment is open-ended, so what a patient pays in month six counts as much as what they pay in month one. Insurance coverage of weight loss drugs varies widely across US plans ^[2], and Lilly has said direct-to-consumer sales account for more than a third of new Zepbound prescriptions ^[2].

The lowest $299 tier belongs to the 2.5 mg vial, which Lilly describes as a starting dose and not an approved maintenance dose. Lilly lists 5 mg, 10 mg or 15 mg as maintenance doses for weight reduction, and 10 mg or 15 mg for obstructive sleep apnea, so many patients would land at the $399 or $449 tiers ^[1]. The company also states that the savings program is not insurance and that its terms can be amended, revoked or ended at any time ^[4].

Whether $449 a month costs a patient more than a compounded product, a different tirzepatide device or cash-pay semaglutide depends on details — dose, insurance status, pharmacy — that the pricing announcement does not address.

What happens next

Separate agreements President Donald Trump signed with Lilly and Novo Nordisk aim to lower the prices the government pays, extend Medicare coverage of obesity drugs to certain patients for the first time, and stock discounted medicines on a government direct-to-consumer site called TrumpRx, scheduled to launch in January ^[2]. The Lilly agreement concerns the Zepbound multi-dose pen and is subject to Food and Drug Administration approval ^[2].

How many patients use Zepbound single-dose vials, and whether these cash prices will move again, has not been reported ^[2].